Invega Shortage Update: What Patients Need to Know in 2026

If you or someone you love takes Invega (paliperidone) for schizophrenia or schizoaffective disorder, you may have heard concerns about availability — or experienced difficulty filling your prescription. Here is the most up-to-date information on the Invega shortage situation in 2026, broken down by formulation.

Is There an Official Invega Shortage in 2026?

As of 2026, oral paliperidone extended-release (generic Invega) is NOT on the FDA's active drug shortage list. Generic versions are manufactured by multiple companies, which has helped stabilize the supply of the oral tablet form. However, there are two important caveats:

Not being on the FDA shortage list does not mean every pharmacy has it in stock. Local and regional gaps can still occur.

The injectable formulations (Invega Sustenna, Trinza, Hafyera) are brand-name specialty medications that may have localized distribution issues separate from the oral tablet supply chain.

Oral Paliperidone ER: What's the Current Status?

Generic paliperidone extended-release tablets are widely available from multiple manufacturers. This competitive market keeps supply more stable than brand-only medications. The brand-name Invega oral tablets, however, are less commonly stocked because most pharmacies and insurance plans substitute the generic.

Patients who specifically require brand-name Invega (e.g., those on a 'dispense as written' prescription for clinical reasons) may have a harder time, as some pharmacies may not maintain brand inventory when generics are available.

Invega Sustenna: Specialty Distribution Challenges

Invega Sustenna (monthly paliperidone palmitate injection) is a specialty medication distributed through a limited network. While it's not officially on a shortage list, patients often report difficulty because:

It requires prior authorization from most insurance plans, which can take 2–4 weeks to process.

It is only available through specialty pharmacies or clinic stock — not at your local retail pharmacy counter.

Cold-chain logistics can create supply gaps, especially in hot climates or remote regions.

In some cases, the medication is billed under the medical benefit (Part B) rather than the pharmacy benefit (Part D), requiring a different coordination process.

Why Do Patients Experience Availability Problems Even Without an Official Shortage?

The FDA shortage database only captures medications that manufacturers have formally reported as having supply disruptions. In practice, patients can still experience:

Low stocking levels. Pharmacies that rarely dispense a medication may not keep sufficient stock on hand.

Insurance barriers. Prior authorizations, step therapy requirements, and formulary restrictions can make it feel like the drug doesn't exist even when pharmacies have it.

Wholesaler allocation. Some manufacturers limit how much product individual pharmacies can order, especially during high-demand periods.

Geographic disparities. Rural and underserved areas may have fewer pharmacies equipped to carry or quickly order specialty antipsychotic medications.

What Should Patients Do Right Now?

If you're having trouble getting your Invega prescription filled in 2026, here's your action plan:

Don't stop taking your medication. Contact your prescriber immediately if you're at risk of running out. They can help with emergency dispensing, samples, or a bridge prescription.

Ask about generic paliperidone ER. If you take oral Invega tablets, the generic is therapeutically equivalent and much more likely to be in stock — with prices as low as $32–$36 with a GoodRx coupon.

Use medfinder to check pharmacies near you.

medfinder calls pharmacies in your area to find who has your medication in stock, then texts you results — removing the need to spend hours on hold.

Contact Janssen CarePath. Call 1-877-227-3728 or visit myjanssencarepath.com to get help with access, insurance navigation, and finding dispensing pharmacies.

Talk to your prescriber about alternatives. If access remains impossible, risperidone (the parent compound) is the most pharmacologically similar bridge medication and is widely available.

The Bottom Line for Patients

There is no active, official shortage of oral paliperidone ER in 2026, but real-world access problems do exist — particularly for injectable formulations and brand-name-only patients. Stay in close contact with your prescriber, explore the generic option, and use all available tools to find your medication. If stock issues continue, read our guide on alternatives to Invega for options your doctor may consider.